Imaging Agents

Chest Radiograph Effective for Excluding Pediatric Pneumonia

September 12, 2018

The researchers found that 72.8% of children had negative CXRs, with 8.9% of these children clinically diagnosed with pneumonia and 9.3% given antibiotics for other bacterial syndromes.

Biomarker Panel May Improve Lung Cancer Risk Assessment

August 06, 2018

The integrated risk prediction model combining smoking exposure with the biomarker score yielded an area under the curve of 0.83 versus 0.73 for a model based on smoking exposure alone.

Post-Endoscopic Infection More Common Than Previously Thought

June 22, 2018

The rates of infections were compared with those after screening mammography, prostate cancer screening, bronchoscopy, and cystoscopy procedures.

FDA: New Med Guide for Patients Receiving Gadolinium-Based Contrast Agents

By May 17, 2018

These Medication Guides should be provided the first time an outpatient receives a GBCA injection at an MRI center; hospital patients are not required to receive a Medication Guide.

Kurtosis Diffusion-Weighted Imaging May Reduce False Positive Mammographies

February 23, 2018

At the predefined sensitivity of greater than 98.0%, the researchers found that the radiomics feature model reduced false-positive results from 66 to 20 in the independent test set (specificity, 70.0%); BI-RADS 4a and 4b lesions benefited from the analysis (74.0 and 60.0%, respectively).

FDA: 'Groundbreaking' Approval Enables Domestic Supply of Critical Medical Isotope

February 09, 2018

New technology approved to produce the country's own supply of the radioisotope Technetium-99m

FDA Expands Pediatric Age Range for MultiHance Contrast Agent

By January 30, 2018

The FDA's approval was supported by data specifically gathered in patients aged <2 years. The 0.1mmol/kg dose significantly improved the visualization and morphologic assessment of CNS lesions as seen in older pediatric patients and adults.

MRI Diagnostic for Differentiating Low-Grade Bladder Cancers

January 29, 2018

Across studies, the pooled sensitivity of MR imaging was 0.90 and the specificity was 0.88 for differentiating tumors staged T1 or lower from those staged T2 or higher.

FDA: New Class Warning for All Gadolinium-Based Contrast Agents

By December 19, 2017

Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function.

New Study Sheds Light on Safety of Gadolinium-Based Contrast Agents

By November 29, 2017

After adjusting for gender, age, education level, baseline neurocognitive performance, and others, the authors reported gadolinium exposure was not a significant predictor of cognitive decline, dementia, diminished neuropsychological performance or diminished motor performance

New Immunoassays Show Improvement in Measuring A&#946;42 in CSF

November 09, 2017

The researchers found that the mass spectrometry-derived Aβ42 values showed higher correlations with the modified Aβ42-INNOTEST, Aβ42-FL, Aβ42-EI, and Aβ42-MSD assays versus the classic Aβ42-INNOTEST assay.

CMR Imaging Role Assessed in Myocarditis Prognosis

October 13, 2017

The researchers found that 98 patients experienced a major adverse cardiovascular event (MACE) at a median follow-up of 4.7 years.

FDA Clears First Seven Tesla MRI Device

By October 12, 2017

The FDA reviewed a 510(k) premarket submission for the device by Siemens and based its clearance on comparison to a predicate device and sample clinical images.

First Fecal Tagging Agent Approved for Virtual Colonoscopy

By September 25, 2017

Tagitol V, a low-volume fecal tagging agent, opacifies remaining stool in the colon for CT imaging. It will be available as a 40% w/v oral suspension in boxes containing three 20mL bottles.

Dotarem Approved for Use in Children Under Two Years Old

By September 06, 2017

The approval was based on a study (n=51) which showed that at the standard dose, the pharmacokinetic and safety profiles for this gadolinium-based contrast agent were similar for patients under the age of 2 and in older children and adults.

Varibar Nectar Approved for Oropharyngeal Function Testing

By July 28, 2017

Varibar Nectar — with target viscosity 300 CPS — comes in an apple flavor for improved patient compliance and is designed to provide the least coating properties necessary to visualize the swallowing process.

FDA Clears First MRI Device for Neonatal Imaging in NICU

By July 21, 2017

The Embrace Neonatal MRI System is specifically designed for imaging of the neonatal head (head circumference up to 38cm and weight of 1 - 4.5kg).

First Fluorescing Agent Approved for Use with Gliomas

By June 08, 2017

The approval was supported by three prospective studies that showed aminolevulinic acid-induced fluorescence was highly predictive for visualizing malignant tissue as verified by histopathology of biopsied fluorescent tissue.

FDA Update on Use of Gadolinium-Based Contrast Agents for MRI

By May 22, 2017

Some of these studies evaluated GBCA use for durations >1 year and showed that gadolinium is retained in organs such as the brain, bones, and skin.

CDC: Cancer Screening 'Considerably' Below Targets

March 07, 2017

The researchers found that screening test use remained considerably below HP2020 targets for selected cancer screening tests.

Diagnostic Digital Mammograms Show Mixed Accuracy Outcomes

March 01, 2017

Digital imaging has improved diagnostic capability of mammograms but the percentage of false-positives is up, too, according to a study published online in Radiology.

Varibar Pudding Approved for Use in Oropharyngeal Evaluation

By February 28, 2017

Bracco Diagnostics announced that the Food and Drug Administration (FDA) has approved Varibar Pudding (barium sulfate) oral paste for modified barium swallow (MBS) examinations to evaluate the oral and pharyngeal function and morphology.

Are ER Physicians 'Choosing Wisely'?

By February 07, 2017

Many emergency physicians are performing low-value services, despite patients being deemed low-risk. The findings come from a cross-sectional sample survey of nearly 800 emergency physicians.

Multi-Parametic MRI May Significantly Reduce Unnecessary Biopsies

January 23, 2017

For men with high serum prostate-specific antigen, multi-parametric magnetic resonance imaging (MP-MRI) is more sensitive but less specific than transrectal ultrasound guided prostate biopsy (TRUS-biopsy) for detecting clinically significant cancer, and can be used as a triage test to avoid unnecessary biopsy, according to a study published online in The Lancet.

FDA: Caution with Implantable Infusion Pumps in MRI Setting

By January 11, 2017

The FDA has received reports of serious adverse events which describe medication dosing inaccuracies and other mechanical problems with the pump that have led to patient injury and death.

Contraindication Lifted for Ultrasound Contrast Agent

By January 11, 2017

Bracco Diagnostics announced that the Food and Drug Administration (FDA) has lifted the contraindication for use of Lumason (sulfur hexafluoride lipid-type A microspheres) in patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts.

Does Gadolinium Exposure Increase Parkinsonism Risk?

July 06, 2016

No significantly increased risk of parkinsonism for patients with cumulative gadolinium exposure

Oraltag Oral Contrast Agent Available for Abdominal CT Scans

By July 05, 2016

Otsuka and Interpharma Praha announced the coming launch of Oraltag (iohexol) for Oral Solution indicated for use in computed tomography (CT) of the abdomen and pelvis to opacify bowel loops and delineate between normal loops and adjacent organs or areas of suspected pathology.

Netspot Approved for Detecting Neuroendocrine Tumors

By June 02, 2016

The Food and Drug Administration (FDA) has approved Netspot (Advanced Accelerator Applications), a radioactive diagnostic agent for positron emission topography (PET) imaging. The probe will aid in locating tumors in patients with somatostatin receptor positive neuroendocrine tumors (NETs), a rare set of tumors which may or may not be cancerous.

Imaging Agent Approved to Detect Recurrent Prostate Cancer

By May 27, 2016

The approval of Axumin was based on two studies to evaluate the safety and efficacy.